TW200602072A - Combination therapy for preventing or treating alzheimer's disease, and kit therefor - Google Patents

Combination therapy for preventing or treating alzheimer's disease, and kit therefor

Info

Publication number
TW200602072A
TW200602072A TW094120199A TW94120199A TW200602072A TW 200602072 A TW200602072 A TW 200602072A TW 094120199 A TW094120199 A TW 094120199A TW 94120199 A TW94120199 A TW 94120199A TW 200602072 A TW200602072 A TW 200602072A
Authority
TW
Taiwan
Prior art keywords
disease
preventing
treating alzheimer
combination therapy
kit therefor
Prior art date
Application number
TW094120199A
Other languages
English (en)
Chinese (zh)
Other versions
TWI350173B (enExample
Inventor
Frank Mattner
Walter Schmidt
Original Assignee
Frank Mattner
Walter Schmidt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frank Mattner, Walter Schmidt filed Critical Frank Mattner
Publication of TW200602072A publication Critical patent/TW200602072A/zh
Application granted granted Critical
Publication of TWI350173B publication Critical patent/TWI350173B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
TW094120199A 2004-07-13 2005-06-17 Combination therapy for preventing or treating alzheimer's disease, and kit therefor TW200602072A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0118504A AT500483B1 (de) 2004-07-13 2004-07-13 Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung

Publications (2)

Publication Number Publication Date
TW200602072A true TW200602072A (en) 2006-01-16
TWI350173B TWI350173B (enExample) 2011-10-11

Family

ID=35115768

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094120199A TW200602072A (en) 2004-07-13 2005-06-17 Combination therapy for preventing or treating alzheimer's disease, and kit therefor

Country Status (14)

Country Link
US (2) US7935348B2 (enExample)
EP (1) EP1765388B8 (enExample)
JP (2) JP5642333B2 (enExample)
KR (1) KR101158600B1 (enExample)
CN (1) CN101022825B (enExample)
AT (1) AT500483B1 (enExample)
AU (1) AU2005261687B8 (enExample)
CA (1) CA2577332C (enExample)
DK (1) DK1765388T3 (enExample)
ES (1) ES2414872T3 (enExample)
PL (1) PL1765388T3 (enExample)
PT (1) PT1765388E (enExample)
TW (1) TW200602072A (enExample)
WO (1) WO2006005706A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
CN101506236B (zh) 2005-11-30 2012-12-12 雅培制药有限公司 抗淀粉样β蛋白的单克隆抗体及其用途
RU2442793C2 (ru) * 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
RU2009128039A (ru) * 2006-12-22 2011-01-27 Дженентек, Инк. (Us) Антагонисты dr6 и способы их применения в лечении неврологических нарушений
EP2124952A2 (en) * 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8586706B2 (en) 2007-10-25 2013-11-19 Kagoshima University Peptide vaccine using mimic molecules of amyloid β peptide
ES2332846B1 (es) 2007-10-26 2010-07-08 Grifols, S.A. Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
AT506820B1 (de) * 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
AT506819B1 (de) * 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
WO2010014702A1 (en) * 2008-07-29 2010-02-04 Medtronic, Inc. Apheresis of a target molecule from cerebrospinal fluid
AU2009313851A1 (en) * 2008-11-13 2010-05-20 Modgene, Llc Modification of amyloid-beta load in non-brain tissue
KR101538361B1 (ko) 2008-12-22 2015-07-22 후지타 헬쓰 유니버시티 Ａβ 제거재, Ａβ 제거기 및 Ａβ 제거 시스템
US20110033463A1 (en) * 2009-08-06 2011-02-10 Medtronic, Inc. Apheresis, administration of agent, or combination thereof
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US10112000B2 (en) 2010-07-08 2018-10-30 Asahi Kasei Medical Co., Ltd. Method for reducing amyloid beta concentration in blood
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
US20120321694A1 (en) * 2010-10-27 2012-12-20 Daniel Larocque Compositions and uses
RS53496B1 (sr) 2011-10-04 2015-02-27 Affiris Ag POSTUPAK ZA DETEKCIJU Aβ-SPECIFIČNIH ANTITELA U BIOLOŠKOM UZORKU
WO2013067157A1 (en) 2011-11-01 2013-05-10 Modgene, Llc Compositions and methods for reduction of amyloid-beta load
CN110133298A (zh) * 2012-03-18 2019-08-16 株式会社资生堂 疾病样品分析装置、分析系统及分析方法
DE102012108598A1 (de) * 2012-09-14 2014-04-10 Forschungszentrum Jülich GmbH Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung
PL3260865T3 (pl) 2012-04-05 2023-04-11 Priavoid Gmbh Sposób obróbki krwi, produktów krwiopochodnych i narządów
DK2834644T3 (da) 2012-04-05 2019-11-04 Forschungszentrum Juelich Gmbh Polymerer, indeholdende multivalente amyloid-beta-bindende d-peptider og deres anvendelse
KR101416954B1 (ko) * 2012-09-12 2014-07-16 한양대학교 산학협력단 조혈세포 분화 유도 방법
EP3116893B1 (en) * 2014-03-11 2019-08-28 Jacques Fantini A chimeric peptide that interacts with cell membrane gangliosides
CN106466298A (zh) * 2015-08-14 2017-03-01 上海交通大学医学院 一种单唾液酸四己糖神经节苷脂修饰的重组脂蛋白及其应用
EP3454885A4 (en) * 2016-05-12 2019-12-25 Ohio State Innovation Foundation PEPTIDES AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
CA3069880A1 (en) * 2017-07-17 2019-01-24 Spark Therapeutics, Inc. Apheresis methods and uses
US12227567B2 (en) 2017-07-25 2025-02-18 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
CN116063520A (zh) 2019-01-30 2023-05-05 真和制药有限公司 抗gal3抗体及其用途
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
CN115957324A (zh) * 2021-10-12 2023-04-14 首都医科大学宣武医院 外周CLU作为靶点在降低脑Aβ中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476715A (en) 1989-10-03 1995-12-19 Fresenius Ag Particulate adsorbent for the removal of biomacromolecules such as LDL and endotoxins from whole blood in extracorporeal circuits
ATE294959T1 (de) 1994-05-13 2005-05-15 Miltenyi Biotec Gmbh An protein gebundene sterile und pyrogenfreie säulen zum binden und entfernen von substanzen aus blut
ES2175325T3 (es) 1997-06-18 2002-11-16 Morse Tec Europe Srl Rueda dentada con perfil de dientes mejorado para funcionamiento mas silencioso.
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
WO2000038760A2 (en) * 1998-12-29 2000-07-06 Occulogix Corporation Rheological treatment methods and related apheresis systems
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
ES2279869T3 (es) * 2001-06-20 2007-09-01 Ramot At Tel Aviv University Ltd. Peptido antigenico comprendido por mulitples copias de un epitope de un polipeptido implicado en enfermedades de formacion de placas y los procedimientos de uso correspondientes.
US20050227941A1 (en) * 2001-12-17 2005-10-13 Karen Duff Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
CA2487528A1 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
AU2003303198A1 (en) * 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
UA87453C2 (ru) * 2003-02-01 2009-07-27 Вайет Применения фрагмента ав для лечения болезни альцгеймера
AT413336B (de) 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
US20050158306A1 (en) * 2004-01-16 2005-07-21 Halikas James A. Treatment for neuro-degenerative disease by a blood cleansing system using monoclonal antibodies
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500835B1 (de) * 2004-09-13 2007-12-15 Affiris Forschungs & Entwicklungs Gmbh Cholinestertransport-protein-mimotop als atherosklerose-medikament

Also Published As

Publication number Publication date
JP2008506665A (ja) 2008-03-06
PL1765388T3 (pl) 2013-09-30
AU2005261687B8 (en) 2011-07-21
AT500483B1 (de) 2006-01-15
DK1765388T3 (da) 2013-07-22
KR20070036158A (ko) 2007-04-02
CN101022825A (zh) 2007-08-22
CA2577332A1 (en) 2006-01-19
ES2414872T8 (es) 2014-11-06
EP1765388B8 (de) 2013-05-29
AU2005261687A1 (en) 2006-01-19
TWI350173B (enExample) 2011-10-11
AU2005261687B2 (en) 2011-02-17
WO2006005706A2 (de) 2006-01-19
CN101022825B (zh) 2015-02-04
US20080051690A1 (en) 2008-02-28
WO2006005706A8 (de) 2006-11-16
AT500483A4 (de) 2006-01-15
CA2577332C (en) 2014-12-09
HK1103354A1 (en) 2007-12-21
WO2006005706A3 (de) 2006-07-20
US7935348B2 (en) 2011-05-03
EP1765388B1 (de) 2013-04-17
PT1765388E (pt) 2013-05-24
JP2013116903A (ja) 2013-06-13
KR101158600B1 (ko) 2012-07-09
US20110201987A1 (en) 2011-08-18
ES2414872T3 (es) 2013-07-23
JP5642333B2 (ja) 2014-12-17
EP1765388A2 (de) 2007-03-28

Similar Documents

Publication Publication Date Title
TW200602072A (en) Combination therapy for preventing or treating alzheimer's disease, and kit therefor
MX2020013335A (es) Metodos novedosos.
EP1613347A4 (en) BETA AMYLOID PEPTIDE DETECTING HUMANIZED ANTIBODIES
WO2008050148A3 (en) Therapy for liver disease
PL374865A1 (en) Treatment of tnf alpha related disorders
TW200509958A (en) Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
IL158921A0 (en) Anti-ngf antibodies for the treatment of various disorders
EP1755458A4 (en) METHOD AND DEVICE FOR THE SELECTIVE TREATMENT OF TISSUE
MXPA05010914A (es) Metodo de tratamiento de la enfermedad de alzheimer.
EA200401525A1 (ru) Способы лечения гепатита (варианты )
WO2007023408A3 (en) 4d image-based planning methods and apparatus for targeted therapy
MX2007000606A (es) Arilidenos para el tratamiento de enfermedades mediadas por receptor alfa relacionado con estrogeno.
TW200637574A (en) Treatment method
EP2279742A3 (en) Combinations for the treatment of immunoinflammatory disorders
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
NO20081835L (no) Behandlingsmetoder ved bruk av oksytocin receptoragonister
WO2006023452A3 (en) Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
IL170519A0 (en) Use of a fibrate and orlistat for the treatment of obesity
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs
SG156658A1 (en) Treatment of diseases
HUP0401317A3 (en) Novel use of subsituted aminomethyl chromans for the treatment of movement disorders and of adverse effects induced by drugs administered to treat extrapyramidal movement disorders
TW200509882A (en) Beauty method

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees